IDO1 and sarcoma: Before investigating the benefit of IDO inhibition in the preclinical sarcoma model, we evaluated the impact of GDC-0919—a novel IDO1 inhibitor—on Kynurenine and Tryptophan levels both at peripheral and tumoral levels.